The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

Glenmark’s progress with a cancer treatment shows the potential of Indian pharma to move from generics to drug discovery.

SIGNIFICANT EVENTS DURING 1 APRIL - 30 JUNE 2025In April, Iconovo announced an organizational change expected to reduce annual costs by approximately 14-16 MSEK starting in the third quarter of 2025.

The Inflation Reduction Act (IRA) made changes to the way drugs are covered and reimbursed in Medicare. It has been anticipated that this could ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS ) between April 29, 2025 and June 23, 2025, both dates inclusive (the ...

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

Overview of Obesity Treatment MarketThe global Obesity Treatment Market is valued at USD 22.2 Billion in 2024 and is projected to reach a value of USD 194.1 Billion by 2035 at a CAGR (Compound Annual ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...

A Cuban restaurant in south Lincoln has temporarily closed, citing an immigration "situation" that "touched our family very ...

The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by ...

Obesity doctors break down exactly what this drug will do week-by-week in terms of side effects and weight loss.